Clearmind Medicine (CSE: CMND) (FSE: CWY0), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics, has announced the fifth webinar in its Psychedelics for Alcoholism series. This segment is titled “Psychedelics for Alcoholism, Q&A with Clearmind Management.”
Scheduled for March 30, 2022, this insightful event will feature Clearmind CEO Adi Zuloff-Shani and business development VP Mark Haden. The two experts will discuss the effects of alcohol use disorder (“AUD”) and provide an overview of the company’s proprietary psychoactive molecule, MEAI. In addition, the webinar will include a question-and-answer session, during which key personnel will answer questions related to MEAI and its potential treatment for AUD and binge drinking.
MEAI has shown significant promise in its ability to break the addiction cycle. Based on studies and research, MEAI works by potentially innervating neural pathways such as 5-HT1A, which leads to decreased impulsivity and to “sensible behavior.” Because 5-HT1A receptors are associated with controlling craving behavior across the board, MEAI may have a wide range of applications beyond binge drinking. This upcoming event will provide crucial information regarding this novel treatment candidate, the rigorous science behind it, and the potential for the treatment to significantly impact this space.
This fifth webinar follows the company’s most recent segment in the series: “Psychedelics for Alcoholism, Investor Deep Dive.” During this webinar, market analyst Marissa Wright provided invaluable insight into the pychedelics market with a focus on psychedelic treatments for alcohol use disorder. After providing a brief explanation of what a sound investment might look like in this market, Wright went on to note key things she looks at when making an investment, such as the valuation spread, exit opportunities and the competitive landscape, including competitive intensity and IP protection.
After explaining that she studied 63 different companies in the space and delved into thousands of data sources, Wright had this to say about Clearmind: “In a summary, what does Clearmind look like? Well, they’re hitting a huge social problem, a $249 billion economic impact problem just in the U.S. The market size based on a model I’ve heard is about $4.2 billion revenue potential.”
Clearmind has “low competitive intensity—they’ve got a new molecule,” she continued, pointing out that this means broad IP protection. In addition, Wright noted that Clearmind’s potential treatment offers a significant body of anecdotal evidence, indicating efficacy in humans, and is not dependent on expensive behavioral therapies; in addition, based on her research, the company has an 11 to 70 times exit opportunity.
“And the alcohol substitute ingredient is a bonus,” Wright concluded. “They’ve got a patent on using MEAI and other psychedelics as a beverage ingredient. What a great way to deliver.”
For more information and registration for the next event in the series, please visit https://ibn.fm/7PBlz
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment